Form 4: Corcept Therapeutics Officer Exercises, Sells Stock

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, exercised stock options, sold shares under a 10b5-1 plan, and acquired new shares and restricted stock awards.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer, exercised 5,000 stock options at $13.56 per share on December 1, 2025.
• Concurrently, Lyon sold 5,000 shares of common stock at a weighted average price of $79.5263 per share on December 1, 2025, as part of a pre-arranged 10b5-1 plan adopted on August 30, 2024.
• Lyon also purchased 178 shares of common stock at $79.78 per share and received 178 unvested restricted stock awards at $0.00 per share under the company's 2024 Incentive Award Plan on December 1, 2025.
• On December 2, 2025, 110 shares were withheld by the Issuer at $79.78 per share to cover tax obligations related to the vesting of restricted stock units.
• Following these transactions, Lyon beneficially owns 10,523 shares of common stock, including 1,165 shares underlying unvested restricted stock awards.
• Lyon retains 11,571 exercisable stock options with an expiration date of February 7, 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's pre-planned (10b5-1), and the officer also acquired new shares and restricted stock awards, indicating continued long-term alignment with the company. The exercise of options at a low strike price is a positive for the officer.

Positives

• Officer exercised stock options at a significantly lower price ($13.56) compared to the market price ($79.5263 $79.78), indicating a substantial personal gain from equity compensation.
• Acquisition of 178 shares under a purchase plan and 178 unvested restricted stock awards demonstrates continued alignment with shareholder interests and future incentives for the officer.

Negatives

• Sale of 5,000 shares, even if pre-planned, reduces the officer's direct common stock holdings.
• 110 shares were withheld for tax obligations, representing a reduction in direct holdings to cover tax liabilities associated with equity vesting.

Risks

• The vesting of 178 restricted stock awards is contingent on the reporting person remaining the beneficial owner of the Purchase Plan Shares through the one-year anniversary of the grant date.
• The vesting of 1,165 shares underlying other restricted stock awards is contingent on the reporting person satisfying certain requirements through their respective one-year anniversaries of the grant dates.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting conditions for restricted stock awards, which are contingent on future service and ownership.

Industry Context

This Form 4 filing details routine insider transactions for an officer of Corcept Therapeutics. Such transactions, particularly those executed under a 10b5-1 plan, are common for executives managing their equity compensation and personal finances and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale of shares by an officer, even if pre-planned, could be perceived neutrally or slightly negatively, but the acquisition of new shares and restricted stock awards demonstrates continued commitment. The exercise of options at a significant profit for the officer is a standard part of executive compensation.
• Employees: The granting of restricted stock awards under an incentive plan is a common form of employee compensation and retention.

Next Steps

• Vesting of 178 restricted stock awards on the one-year anniversary of December 1, 2025, contingent on the reporting person remaining the beneficial owner of the Purchase Plan Shares.
• Vesting of 216, 749, and 200 restricted stock awards on the one-year anniversary of their respective grant dates (March 3, 2025, June 2, 2025, and September 2, 2025), contingent on the reporting person satisfying certain requirements.

Key Dates

Recommendation

The filing details routine insider transactions by a key officer, including the exercise of stock options, a pre-planned sale of shares, and the acquisition of new equity awards. These actions are typical for executive compensation and personal financial management and do not indicate a significant change in the company's fundamental outlook or operational performance. The pre-planned nature of the sale (10b5-1 plan) suggests it is not driven by new, adverse information. Therefore, based solely on this Form 4, a 'hold' recommendation is appropriate as there is no new information to warrant a change in investment thesis.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Options, Restricted Stock Units, 10b5-1 Plan, Joseph Douglas Lyon, Officer Transactions, Equity Compensation